Form 4: HEALTHEQUITY EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
HEALTHEQUITY's EVP and General Counsel, Delano Ladd, sold 1,500 shares of common stock for $94.72 per share, reducing his direct beneficial ownership to 73,979 shares, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Delano Ladd, Executive Vice President and General Counsel of HEALTHEQUITY, INC. (HQY), reported a sale of company common stock.
- The transaction involved the disposition of 1,500 shares of Common Stock.
- The sale occurred on December 19, 2025, at a price of $94.72 per share.
- Following this transaction, Delano Ladd directly beneficially owns 73,979 shares of HEALTHEQUITY Common Stock.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Ladd on June 12, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider selling can be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, adverse information, suggesting it's part of personal financial planning.
Positives
- The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.
Negatives
- Insider selling, even when pre-planned, can sometimes be perceived by investors as a lack of confidence in the company's near-term prospects, although this is not necessarily the case with 10b5-1 plans.
Industry Context
This filing is specific to an individual insider transaction and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transaction was executed under a Rule 10b5-1 trading plan, which is a corporate governance mechanism designed to allow insiders to sell shares without being accused of trading on material non-public information. | June 12, 2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reporting person. |
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it's not a reaction to new company developments.
Key Dates
| Date | Description |
|---|---|
| June 12, 2025 | Date the Rule 10b5-1 trading plan was adopted by Delano Ladd. |
| December 19, 2025 | Date of the reported transaction (sale of common stock). |
| December 23, 2025 | Date the Form 4 filing was signed and submitted. |
Keywords
HEALTHEQUITY, HQY, Insider Trading, Form 4, Stock Sale, Delano Ladd, EVP, General Counsel, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.